IP Library Granted Patent US 8,399,618
Granted Patent B2
US 8,399,618 · App. 13/336,907 · Granted Mar 19, 2013

Immunoglobulin insertions, deletions, and substitutions

Inventors: Gregory Alan Lazar (Los Angeles, CA); Bassil I. Dahiyat (Altadena, CA); Wei Dang (Pasadena, CA); Sher Bahadur Karki (Pomona, CA); Omid Vafa (Monrovia, CA)
Assignee: Xencor, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,399,618
App. No.
13/336,907
Granted
Mar 19, 2013
Kind
B2
Abstract

An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more FcγRs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide.

Claims (9)

1. A protein comprising a variant Fc region of a parent Fc polypeptide, wherein said variant Fc region comprises a first substitution at position 328 and a second substitution at or an insertion after position 236 , wherein said first substitution is arginine, said second substitution is arginine, and said insertion is arginine, wherein said protein exhibits ablated binding affinity to more than one FcγR as compared to said parent polypeptide and numbering is according to the EU index as in Kabat.

2. The protein of claim 1 , wherein said protein is an antibody.

3. The protein of claim 2 , wherein said antibody is selected from the group consisting of a human antibody, a humanized antibody, and a monoclonal antibody.

4. The protein of claim 3 , wherein said antibody is a humanized.

5. The protein of claim 1 , wherein said protein exhibits ablated binding affinity to FcγRI and FcγRIIb.

6. The protein of claim 1 , wherein said protein exhibits ablated binding affinity to FcγRIIa and FcγRIIb.

7. The protein of claim 1 , wherein said protein exhibits ablated binding affinity to FcγRIIb and FcγRIIIa.

8. The protein of claim 2 , wherein said antibody further comprises an engineered glycoform.

9. The protein of claim 2 , wherein said antibody has specificity for a target antigen selected from the group consisting of A33, BAFF-R, CA 125, CD5, CD19, CD20, CD30, CD33, CD38, CD40, CD44, CD52, CD123, CD138, CEA, EGFR (ErbB-1), EpCAM, GD2, GD3, Her2/neu (ErbB-2), HM1.24, IGF-1R, IL-5R, IL-6R, integrin alpha5, integrin alpha5/beta1, integrin alpha5/beta3, Lewis Y related carbohydrate, MCAM (melanoma cell adhesion molecule), PSCA (prostate stem cell antigen), PSMA (protage specific membrane antigen), STEAP (six-transmembrane epithelial antigen of the prostate), and TAG-72 (tumor-associated glycoprotein-72).

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2023
From: LAZAR, GREGORY ALAN; DAHIYAT, BASSIL I.; DANG, WEI; KARKI, SHER BAHADUR; VAFA, OMID
To: XENCOR, INC.
Reel/Frame 063736/0494 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2023
From: LAZAR, GREGORY ALAN; DANG, WEI; DESJARLAIS, JOHN R.; KARKI, SHER BAHADUR
To: XENCOR, INC.
Reel/Frame 063736/0528 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2023
From: DAHIYAT, BASSIL I.; DANG, WEI; VAFA, OMID
To: XENCOR, INC.
Reel/Frame 063736/0539 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2023
From: LAZAR, GREGORY ALAN; KARKI, SHER BAHADUR
To: XENCOR, INC.
Reel/Frame 063736/0552 →
Continuity (9)
Continuation 12020443 · Jan 25, 2008
Continuation In Part 11396495 · Mar 31, 2006
Continuation In Part 11256060 · Oct 21, 2005
Provisional Application 60886635 · Jan 25, 2007
Provisional Application 60659004 · Mar 3, 2005
Provisional Application 60652968 · Feb 14, 2005
Provisional Application 60629068 · Nov 18, 2004
Provisional Application 60621387 · Oct 21, 2004
Related Publication 20120225058A1 · Sep 6, 2012